Keylika
YC S22San Francisco, US · Founded 2022 · 1 employees · 1 known investors
Keylika develops a platform synthesis technology for mixed ligand metal complexes to generate organometallic drugs for treating therapeutic conditions including hematology, pain, inflammation, metabolic disorders, infectious diseases, and oncology. The company combines drug development with drug delivery technologies, customizing molecular structure and formulation to optimize clinical outcomes for women, children, elderly, and patients with specific diseases.
BiotechHealthtechMedical DevicesAI-powered Drug DiscoveryDrug DeliveryNanotechnologyTherapeuticsUnited States of AmericaAmerica / CanadaPartly Remote
Founders & leadership· Y Combinator alumni (S22)
Keylika was founded in 2022 by Buddha Chaudhuri, Frederik Ceyssens, Buddhadev P. Chaudhuri, PhD, and Frederik Ceyssens, PhD.
BC
Buddha Chaudhuriin𝕏CEO & Co-FounderBuddha Chaudhuri led technology development for a microneedle biosensor at a Series B medtech company and has spent 15 years developing healthcare technologies across research institutes and biotech firms. He holds a PhD in Drug Delivery Microsystems from KU Leuven/Imec and completed a postdoctoral fellowship at UCSF/UC Berkeley.
FC
Frederik CeyssensinCo-founder · CTOFrederik Ceyssens holds a PhD and Masters in IC design along with a Bachelor's in Medicine, and has spent 15 years developing microtechnologies for life science applications before founding Keylika, a neurotech venture focused on vision restoration.
BP
Buddhadev P. Chaudhuri, PhDin𝕏CEO & Co-Founder
FC
Frederik Ceyssens, PhDCTO & Co-Founder
Investors · 1
The YC application· Summer 2022 batch
What they told YC
- Describe what your company does in 50 characters or less.
- The company develops metallodrugs aimed at unmet medical needs.
Summarized from the founders' answers on their Y Combinator profile.
In the news
Frequently asked questions
- What does Keylika do?
- Keylika develops a platform synthesis technology for mixed ligand metal complexes to generate organometallic drugs for treating therapeutic conditions including hematology, pain, inflammation, metabolic disorders, infectious diseases, and oncology. The company combines drug development with drug delivery technologies, customizing molecular structure and formulation to optimize clinical outcomes for women, children, elderly, and patients with specific diseases.
- Who founded Keylika?
- Keylika was founded by Buddha Chaudhuri, Frederik Ceyssens, Buddhadev P. Chaudhuri, PhD, Frederik Ceyssens, PhD in 2022.
- Who are Keylika's investors?
- Keylika's investors include Y Combinator.
- Where is Keylika headquartered?
- Keylika is headquartered in San Francisco, US.